Glenmark launches FabiFlu drug for COVID-19 after DCGI nod
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Glenmark Pharmaceuticals on 20th June said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19, after receiving manufacturing and marketing approval from the Drugs Controller General of India (DCGI) on 19th June.

• FabiFlu has demonstrated an encouraging response with clinical improvement of up to 88 percent in mild to moderate Covid-19 cases during clinical trials, Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.

• Moreover, it is orally administered, and so it serves as a more convenient treatment option over other intravenously administered medications, he noted.

• The drug will be available as a prescription-based medication for Rs 103/tablet, with recommended dose being 1,800 mg twice on day one, followed by 800 mg twice daily up to day 14.

• Favipiravir can be used for coronavirus patients with co-morbid conditions such as diabetes and heart disease with mild to moderate Covid-19 symptoms.

• It offers a rapid reduction in viral load within four days and provides a faster symptomatic and radiological improvement, the drugmaker added.

• Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections.

Source: https://www.hindustantimes.com/india-news/glenmark-launches-covid-19-drug-after-dcgi-nod/story-kwOjjcAbv7zQ1Sksw8qXbP.html
Dr. A●●●●●l S●●●●a and 74 others like this60 shares
Like
Comment
Share
H●●●●●●●a I●●r
H●●●●●●●a I●●r General Medicine
What is the mechanism of action of this drug?
Jun 23, 2020Like1
Dr. A●●●i N●●●●●●●●r
Dr. A●●●i N●●●●●●●●r Internal Medicine
It inhibits viral RNA polymerase.
Jun 23, 2020Like3
Dr. A●●●i N●●●●●●●●r
Dr. A●●●i N●●●●●●●●r Internal Medicine
It inhibits viral RNA polymerase.
Jun 23, 2020Like2